Match Document Document Title
US20110008422 SYSTEM FOR DELIVERY OF PROTEIN IN INSOLUBLE FIBRILLAR OR AGGREGATE FORM  
A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or...
US20150190344 FORMULATIONS FOR DELIVERING INSULIN  
Oral insulin formulations and processes for preparing oral insulin formulations are provided.
US20120201857 Transdermal delivery system for therapeutics  
The present invention provides a method and product for transdermal delivery of therapeutics, including neurotoxins and methods for use thereof. The method and system comprises pharmaceutical...
US20150071879 Stabilization of Aqueous Compositions of Proteins with Displacement Buffers  
An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least...
US20150258178 INTRANASAL INSULIN ADMINISTRATION FOR THE PREVENTION OF ANESTHESIA-INDUCED TAU PATHOLOGY/TAUOPATHIES  
Intranasal administration of insulin for a predetermined period prior to anesthesia significantly prevented anesthesia-induced tau hyperphosphorylation and cognitive impairment and enhanced brain...
US20050181971 Treatment of type i diabetes mellitus  
Use of a growth hormone antagonist to reduce the overnight insulin requirement of a patient suffering from Type I diabetes mellitus or from dawn phenomenon.
US20140031280 METHODS FOR PREVENTING AND TREATING POST-TRAUMATIC STRESS DISORDER (PTSD)  
Methods for preventing and/or treating symptoms of Post-Traumatic Stress Disorder (PTSD) are provided. The preferred method comprises administration of an effective amount of insulin to the upper...
US20130156817 SURFACE IMMOBILIZED CHAPERONES  
A container containing a therapeutic protein, characterized in that chaperones molecules are bound by a molecular linker to an inner surface of the container. The linker being interposed between...
US20150065421 BASAL INSULIN THERAPY  
The present invention relates to the use of use of a long-acting insulin, in particular insulin glargine, in a method of reducing the risk of progression to type 2 diabetes in a patient, a method...
US20130034589 pH-SENSITIVE NANOPARTICLES FOR ORAL INSULIN DELIVERY  
The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The...
US20140349926 FORMULATIONS FOR THE TREATMENT OF DIABETES  
Disclosed is a formulation for parenteral administration comprising insulin that comprises a pH memory between 1 to 4 or between 6 to 8 and an aprotic polar solvent, wherein the insulin is...
US20110039769 INSULIN ALBUMIN CONJUGATES  
Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients.
US20130172246 INSULIN GLARGINE VERSUS METFORMIN FOR THE FIRST-LINE TREATMENT OF EARLY TYPE-2 DIABETES  
The invention relates to a method for treating type 2 diabetes patients, wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective, wherein...
US20110311442 DIRECT CELLULAR ENERGY DELIVERY SYSTEM  
A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group...
US20140178331 METHOD OF TREATING CEREBRAL HEMORRHAGE AND SUBARACHNOID HEMORRHAGE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY  
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are...
US20100143484 ORAL SUBMICRON PARTICLE DELIVERY SYSTEM FOR PROTEINS AND PROCESS FOR ITS PRODUCTION  
The invention provides a novel submicron system for the oral administration of proteins. An effective oral carrier for proteins should shield its content against the gastrointestinal tract...
US20140162947 Kruppel-like Factor 10 (KLF10) as a Biomarker of Endothelial Progenitor Cell Dysfunction  
The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor...
US20140179597 Method for the treatment and prevention of Alzheimer's disease and central nervous system dysfunction  
Intranasal insulin is beneficial for the treatment of Alzheimer's disease and other neurologic disorders. But commercial insulin preparations use metacresol, phenol, and other preservatives for...
US20150011864 Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease  
A method for preventing cognitive decline, comprises the steps of identifying, in an individual, a first stage of cognitive decline corresponding to Subjective Cognitive Impairment and...
US20110091543 ORAL DELIVERY OF MODIFIED TRANSFERRIN FUSION PROTEINS  
Pharmaceutical compositions containing modified fusion proteins of transferrin and therapeutic proteins or peptides with increased serum half-life or increased serum stability are disclosed....
US20120269882 Brain Delivery of Insulin to Treat Systemic Inflammation  
Methods and composition for the treatment of systemic inflammation, such as bacterial or viral sepsis, are described. Methods of treating systemic inflammation comprise delivery of insulin to the...
US20120195959 METHOD FOR TREATING DISEASE OR DISORDER OF ADULT CENTRAL NERVOUS SYSTEM ASSOCIATED WITH TISSUE SHRINKAGE OR ATROPHY BY ADMINISTRATION OF INSULIN  
The present invention provides a use of an insulin for manufacture of a medicament for treating or preventing a disorder or disease of a central nervous system of an adult individual, wherein the...
US20130034602 ENTERIC-COATED CAPSULE CONTAINING CATIONIC NANOPARTICLES FOR ORAL INSULIN DELIVERY  
The invention relates to an enteric-coated capsule containing cationic nanoparticles for oral insulin delivery, in particular to a type of cationic nanoparticle including a polycationic and...
US20150025004 KIDNEY FUNCTION BIOMARKERS  
The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a...
US20140120161 VECTOR FOR ORAL ADMINISTRATION  
A vector for the oral administration of at least one pharmacologically active substance enabling the active substance to move from the intestinal lumen to the blood, optionally via interstitial...
US20110021974 RETINITIS PIGMENTOSA TREATMENT AND PROPHALAXIS  
The invention relates to a method of instilling insulin ophthalmic drops in the conjunctival sac for treating retinitis pigmentosa due to any etiological factors both genetic and non genetic. The...
US20140206611 LONG-ACTING INSULIN FORMULATIONS  
The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
US20110301081 LONG-ACTING FORMULATIONS OF INSULINS  
The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.
US20110256203 POROUS CERAMIC SCAFFOLD HAVING AN ORGANIC/INORGANIC HYBRID COATING LAYER CONTAINING BIOACTIVE FACTOR AND METHOD THEREOF  
A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid composite coating layer containing a bioactive factor is disclosed. The method includes; forming a porous...
US20100297105 ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B  
Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
US20140199398 HIGH CAPACITY DIEKTOPIPERAZINE MICROPARTICLES AND METHODS  
Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl...
US20150157735 PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY  
The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug...
US20140011739 PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY  
The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug...
US20120003296 NEW METHODS OF TREATING DRY EYE SYNDROME  
The invention relates to a method of insulin eye drops for treating dry eye syndrome due to any and all etiological factors (Keratoconjunctivitis sicca), including Sjogren's syndrome, Meibomian...
US20140219954 DRY POWDER FORMULATIONS OF ORGANIC MACROMOLECULES  
The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium...
US20110144011 Cellular Activation Insulin Therapy  
Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is...
US20140023615 THERMO-SENSITIVE, MUCOADHESIVE OR DERMOADHESIVE, AND PENETRATION-ENHANCING FORMULATIONS FOR TOPICAL DELIVERY OF THERAPEUTICS  
The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment,...
US20120093798 Methods for Treatment of Stroke or Cerebrovascular  
Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a...
US20110135596 FUSION PROTEIN COMPRISING UBIQUITIN OR UBIQUITIN-LIKE PROTEIN, MEMBRANE TRANSLOCATION SEQUENCE AND BIOLOGICALLY ACTIVE MOLECULE AND USE THEREOF  
A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a...
US20150045295 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY  
A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with...
US20140007873 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY  
A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with...
US20130338065 DRY POWDER INHALER AND SYSTEM FOR DRUG DELIVERY  
A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with...
US20140255384 METHODS OF TREATING AND PREVENTING SOCIAL COMMUNICATION DISORDER IN PATIENTS BY INTRANASAL ADMINISTRATION OF INSULIN  
Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The...
US20140052051 PERMEANT DELIVERY SYSTEM AND METHODS FOR USE THEREOF  
Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a...
US20110190688 Permeant Delivery System and Methods for Use Thereof  
Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a...
US20150050332 IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES THEREOF, AND POLYCAPROLACTONE PARTICLES AS SCAFFOLDS FOR TISSUE REGENERATION  
In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to...
US20110091421 Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases  
The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on...
US20120087859 NANOCARRIER HAVING ENHANCED SKIN PERMEABILITY, CELLULAR UPTAKE AND TUMOUR DELIVERY PROPERTIES  
The present invention relates to a biopolymer-modified nanocarrier in which chitosan is bound to a water-soluble biocompatible polymer that has been crosslinked via a photo-crosslinkable...
US20130090288 Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes  
The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at...
US20140341845 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION RELATED DISORDERS  
Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a...